- Companies
- Merck KGaA
Merck KGaA Valuation Multiples
Merck KGaA is valued at $70B as of October 2026, a 3.3x revenue multiple. In the last 12 months, Merck KGaA revenue was $24B and Merck KGaA EBITDA was $6.9B.
Merck KGaA Overview
About Merck KGaA
Merck KGaA operates in three main segments: life science, electronics, and healthcare. The life science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
Founded
1668
HQ
Employees
62.5K
Website
Financials (LTM)
EV
$80B
Valuation Multiples
Start free trialMerck KGaA Financials
Merck KGaA reported last 12-month revenue of $24B and EBITDA of $6.9B.
In the same LTM period, Merck KGaA generated $14B in gross profit, $6.9B in EBITDA, and $4B in net income.
Revenue (LTM)
Merck KGaA P&L
In the most recent fiscal year, Merck KGaA reported revenue of $24B and EBITDA of $5.2B.
Merck KGaA is profitable as of last fiscal year, with gross margin of 59%, EBITDA margin of 22%, and net margin of 12%.
Financial data powered by Morningstar, Inc.
Merck KGaA Stock Performance
Merck KGaA has current market cap of $70B, and enterprise value of $80B.
Market Cap Evolution
Merck KGaA's stock price is $160.79.
Merck KGaA share price increased by 2.4% in the last 30 days, and by 22.4% in the last year.
Merck KGaA has an EPS (earnings per share) of $6.73.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $80B | $70B | 1.2% | 2.4% | -2.7% | 22.4% | $6.73 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMerck KGaA Valuation Multiples
Merck KGaA trades at 3.3x EV/Revenue multiple, and 11.6x EV/EBITDA.
EV / Revenue (LTM)
Merck KGaA Financial Valuation Multiples
As of October 17, 2026, Merck KGaA has market cap of $70B and EV of $80B.
Merck KGaA has a P/E ratio of 17.3x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Merck KGaA Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Merck KGaA Margins & Growth Rates
Merck KGaA grew revenue by 2% and EBITDA by 34% in the last fiscal year.
In the most recent fiscal year, Merck KGaA reported gross margin of 59%, EBITDA margin of 22%, and net margin of 12%.
Merck KGaA Margins
Merck KGaA Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Merck KGaA Operational KPIs
Merck KGaA's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Merck KGaA's Rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Merck KGaA's Rule of X is 34% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Merck KGaA Competitors
Merck KGaA competitors include Chugai Pharma, CSL, Takeda Pharmaceuticals, Regeneron, Moderna, argenx, Lonza Group, Bayer, Teva Pharmaceuticals and Jiangsu Hengrui Pharma.
Most Merck KGaA public comparables operate across Biopharmaceuticals, Life Sciences Tools, Advanced Materials, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $8B | $3.8B | 7.5x | 7.0x | 15.9x | 13.3x | |||
| $16B | ($2.6B) | 4.8x | 4.8x | (28.4x) | 14.3x | |||
| $29B | $4.8B | 3.2x | 3.1x | 18.9x | 12.2x | |||
| $14B | $5.1B | 5.3x | 4.5x | 14.9x | 11.3x | |||
| $1.9B | ($2.9B) | 43.3x | 40.2x | (29.1x) | (26.3x) | |||
| $4.2B | $1.1B | 11.1x | 8.0x | 40.4x | 25.6x | |||
| $7.9B | $2.5B | 7.0x | 6.4x | 22.6x | 19.5x | |||
| $51B | $3.4B | 1.7x | 1.7x | 25.3x | 7.8x | |||
This data is available for Pro users. Sign up to see all Merck KGaA competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by Merck KGaA
Merck KGaA has acquired 12 companies to date.
Last acquisition by Merck KGaA was on June 24th 2026. Merck KGaA acquired Bio-Techne for $11B (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Merck KGaA
| Description | Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%. | - | SpringWorks Therapeutics is a Stamford-headquartered clinical-stage biopharmaceutical company developing precision oncology medicines. The lead candidate nirogacestat targets desmoid tumors and received FDA approval in 2023. Pipeline includes gamma secretase inhibitors for solid tumors with Notch pathway activation. Founded in 2017, SpringWorks partners with Roche and Bayer, advancing Phase 3 trials across multiple cancers. The firm trades on NASDAQ under SWTX. | UnitySC is a French firm specializing in metrology and inspection tools for advanced semiconductor packaging. Headquartered in Grenoble, the company supplies defect inspection systems to automotive, high-performance computing, and Internet of Things manufacturers worldwide, backed by global service networks. | |
| HQ Country | |||||
| HQ City | Minneapolis, MN | - | Stamford, CT | Grenoble | |
| Deal Date | 24 Jun 2026 | 15 Oct 2025 | 28 Apr 2025 | 1 Nov 2024 | |
| Valuation | $11B | undisclosed | $3.4B | $173M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Merck KGaA acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Merck KGaA
Merck KGaA has invested in 4 companies to date.
Latest investment by Merck KGaA was on November 20th 2025. Merck KGaA invested in Cassidy Bio in their $8M Seed round (EV/Revenue multiple available to Pro users).
Latest Investments by Merck KGaA
| Description | Cassidy Bio is a San Francisco-based biotechnology company building AI foundation models for genomic analysis to identify novel drug targets. Its platform processes multi-omics data for precision medicine applications in oncology and rare diseases. | INBRAIN Neuroelectronics is a Barcelona, ESP-based operating company active in Medical Devices, Pure-Play AI Software. INBRAIN Neuroelectronics is a Barcelona-based neurotechnology firm developing the first graphene-based brain-computer interface platform for precision neurology. Its therapeutics target Parkinson's disease, epilepsy, and stroke recovery via real-time neural decoding and micrometric stimulation for adaptive treatments. The AI-powered system enables continuous monitoring and automated therapy adjustments. Partnerships include Merck KGaA, with subsidiary INNERVIA Bioelectronics expanding to peripheral nerves and systemic applications. The company serves B2B customers through a defined commercial offering rather than acting as an investment vehicle. Its recorded revenue model is Product sales, describing how customers pay for the operating product or service. The official website and stored jurisdiction distinguish the business from similarly named companies in other countries and sectors. ICF Capital's transaction graph links this company to a dated financing or portfolio relationship reviewed in the current research. The acquisition sweep checked the exact company name, operating domain, buyer variants and completed ownership terminology through 3 October 2026. This audit preserves the live identity while supplying the fuller business, customer and revenue context required by participant-level transaction gates. | Idrx is a Shanghai-based clinical-stage biopharmaceutical company focused on precision oncology therapies for gastrointestinal stromal tumors. It engineers drug combinations targeting tumor escape mechanisms to extend treatment responses. The pipeline includes KIT-mutant inhibitors in Phase 1/2 trials, addressing unmet needs in resistant patient populations worldwide. | - |
| HQ Country | ||||
| HQ City | Tel Aviv | Barcelona | - | - |
| Deal Date | 20 Nov 2025 | 29 Oct 2024 | 7 Aug 2024 | 3 Apr 2024 |
| Round | Seed | Series B | Series B | Series A |
| Raised | $8M | $50M | $120M | $14M |
| Investors | Merck KGaA; 10D; AstraZeneca; lool ventures; Ahren Innovation Capital | Merck KGaA; European Innovation Council; Vsquared Ventures; Avançsa; Next Tech Fund; Aliath Bioventures; Asabys Partners; Centre for the Development of Industrial Technology (CDTI); imec.xpand | Merck KGaA; Nextech Invest; Forge Life Science Partners; Casdin Capital; Blackstone; Andreessen Horowitz; RA Capital Management; Commodore Capital; Nick Lydon | Merck KGaA; M Ventures; Grove Ventures |
| Valuation | undisclosed | undisclosed | $415M | undisclosed |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Merck KGaA investments and their VC round multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Merck KGaA
| When was Merck KGaA founded? | Merck KGaA was founded in 1668. |
| Where is Merck KGaA headquartered? | Merck KGaA is headquartered in Germany. |
| How many employees does Merck KGaA have? | As of today, Merck KGaA has over 62K employees. |
| Is Merck KGaA publicly listed? | Yes, Merck KGaA is a public company listed on Deutsche Börse Xetra. |
| What is the stock symbol of Merck KGaA? | Merck KGaA trades under MRK ticker. |
| When did Merck KGaA go public? | Merck KGaA went public in 1995. |
| Who are competitors of Merck KGaA? | Merck KGaA main competitors include Chugai Pharma, CSL, Takeda Pharmaceuticals, Regeneron, Moderna, argenx, Lonza Group, Bayer, Teva Pharmaceuticals, Jiangsu Hengrui Pharma. |
| What is the current market cap of Merck KGaA? | Merck KGaA's current market cap is $70B. |
| What is the current revenue of Merck KGaA? | Merck KGaA's last 12 months revenue is $24B. |
| What is the current revenue growth of Merck KGaA? | Merck KGaA revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Merck KGaA? | Current revenue multiple of Merck KGaA is 3.3x. |
| What is the current EBITDA of Merck KGaA? | Merck KGaA's last 12 months EBITDA is $6.9B. |
| What is Merck KGaA's EBITDA margin? | Merck KGaA's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Merck KGaA? | Current EBITDA multiple of Merck KGaA is 11.6x. |
| What is the current FCF of Merck KGaA? | Merck KGaA's last 12 months FCF is $2.9B. |
| What is Merck KGaA's FCF margin? | Merck KGaA's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Merck KGaA? | Current FCF multiple of Merck KGaA is 28.1x. |
| How many companies Merck KGaA has acquired to date? | As of October 2026, Merck KGaA has acquired 12 companies. |
| In how many companies Merck KGaA has invested to date? | As of October 2026, Merck KGaA has invested in 4 companies. |
| What was the last Merck KGaA investment? | On 20th November 2025 Merck KGaA invested in Cassidy Bio, participating in a $8M Seed round, alongside 10D, AstraZeneca, lool ventures, and Ahren Innovation Capital. |
| In what companies Merck KGaA invested in? | Merck KGaA invested in Idrx, INBRAIN Neuroelectronics, Nucleai, and Cassidy Bio. |
See public comps similar to Merck KGaA
Lists including Merck KGaA
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




